Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoder ...
Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoder ...
Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising. MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of t ...